| 7 0.25 (3.7%) | 11-19 14:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.87 | 1-year : | 9.81 |
| Resists | First : | 7.59 | Second : | 8.39 |
| Pivot price | 7.49  |
|||
| Supports | First : | 6.3 | Second : | 5.24 |
| MAs | MA(5) : | 7.21 |
MA(20) : | 7.6 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.7 |
D(3) : | 30.4 |
| RSI | RSI(14): 40.7  |
|||
| 52-week | High : | 9.98 | Low : | 5.9 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NSRX ] has closed above bottom band by 12.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 7 - 7.05 | 7.05 - 7.09 |
| Low: | 6.41 - 6.45 | 6.45 - 6.5 |
| Close: | 6.92 - 7 | 7 - 7.07 |
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Tue, 18 Nov 2025
Nasus Pharma Initiates Phase 2 Study of Needle-Free Epinephrine - TipRanks
Tue, 18 Nov 2025
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed - GlobeNewswire
Thu, 06 Nov 2025
Nasus Pharma Announces Approval from Health Canada to - GlobeNewswire
Thu, 06 Nov 2025
Nasus Pharma (NYSE: NSRX) obtains Health Canada authorization to start Phase 2 NS002 study - Stock Titan
Tue, 30 Sep 2025
Nasus Pharma Ltd. Secures Additional Funding from IPO Over-Allotment - TipRanks
Mon, 29 Sep 2025
Laidlaw initiates Nasus Pharma stock with Buy rating on anaphylaxis drug - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|